Kerala Reports New Nipah Virus Case As Woman Tests Positive; Know Fatal Symptoms Of This Zoonotic Infection?

Updated May 9, 2025 | 12:12 PM IST

SummaryA 42-year-old woman in Kerala's Malappuram district has tested positive for the deadly Nipah virus, confirmed by NIV-Pune, prompting immediate containment efforts by the state health authorities.
Kerala Reports New Nipah Virus Case As Woman Tests Positive; Know The Fatal Symptoms Of This Zoonotic Infection?

Credits: Canva

A 42-year-old woman in Malappuram, Kerala, was admitted to a private hospital with severe symptoms resembling encephalitis. Just days later, her worst fears were confirmed — she had contracted the Nipah virus. On Thursday, the National Institute of Virology (NIV) in Pune officially verified the infection, thrusting Kerala once again into the national spotlight as it battles another outbreak of this deadly zoonotic disease.

As Health Minister Veena George heads to Malappuram to monitor the containment strategies, public health concerns are intensifying, especially given the virus’s history in the state and the high fatality rate associated with it. Here’s everything you need to know about the Nipah virus, how it spreads, and why it’s resurfacing now.

Kerala is no stranger to the Nipah virus. Since 2018, the state has witnessed five outbreaks, leading to 22 confirmed deaths. The first outbreak in 2018 was particularly catastrophic — 17 of the 18 infected individuals died, leaving public health systems scrambling for solutions. Further cases occurred in 2019, 2021, and 2023, most commonly between May and September, the region’s monsoon season, which is also marked by a surge in respiratory infections and influenza-like illnesses.

These seasonal overlaps make early diagnosis challenging, as Nipah symptoms often mimic more common illnesses. In 2023 alone, Malappuram reported two deaths linked to the virus. Of all the confirmed infections since 2018, only six individuals have survived, underscoring the virus’s high mortality rate and the need for rapid medical intervention.

How the Virus Is Contracted?

Nipah virus is a zoonotic pathogen, meaning it spreads from animals to humans. Scientific investigations from previous outbreaks, including a joint field survey by the National Institute of Virology (NIV) and the National Institute of High Security Animal Diseases (NIHSAD), found a clear link between fruit bats (commonly known as flying foxes) and human infections.

The virus strain detected in Kerala is closely related to the Bangladeshi strain, notorious for its person-to-person transmission and high mortality, estimated by experts to be up to 90% in some cases. In the 2023 outbreak, antibodies were found in fruit bats from Pandikkad village, strongly pointing to them as the source of the infection.

The consumption of contaminated fruits or exposure to bat saliva and urine on fruits is believed to be one of the primary routes of transmission in initial cases.

What is Nipah Virus?

First identified in Malaysia in 1998, Nipah virus gets its name from the village of Sungai Nipah, where the initial outbreak occurred. The virus belongs to the Henipavirus genus and has since been recognized as one of the world’s most dangerous pathogens due to its pandemic potential and high case fatality rate — estimated to range between 40% and 75%, depending on the outbreak response and healthcare access.

Early symptoms are often non-specific and include:

  • Headache
  • Muscle pain
  • Vomiting
  • Sore throat

As the disease progresses, some patients experience acute respiratory distress, neurological complications like encephalitis, seizures, and altered mental states, which may rapidly lead to coma or death.

Is the Virus Contagious and Airborne?

Yes, Nipah virus is both contagious and airborne. It spreads primarily through respiratory droplets, bodily fluids such as saliva, urine, feces, and blood, and via direct contact with infected individuals or animals.

Healthcare providers and family members caring for infected patients are particularly at risk. This is why strict infection control measures, including personal protective equipment (PPE) and isolation protocols, are crucial to preventing person-to-person spread.

Why Prevention Is Critical?

Currently, there is no specific antiviral treatment or licensed vaccine available for Nipah virus. Medical care is supportive and symptomatic, focusing on:

Hydration and rest

Medications for fever and pain (e.g., acetaminophen, ibuprofen)

Treatment for nausea, seizures, and respiratory distress

Use of inhalers or nebulizers in case of breathing difficulties

Experimental therapies, such as monoclonal antibody treatments, are under research but not yet widely accessible. Given the lack of curative options, early detection and containment remain the most effective ways to manage an outbreak.

Containment Measures Followed in Kerala

Since the first outbreak, Kerala’s public health system has developed a robust protocol to respond to Nipah cases. Isolation wards, contact tracing, and real-time epidemiological surveillance are quickly deployed. The state has also worked closely with central agencies like NIV and WHO to bolster its diagnostic and response capabilities.

With this latest case in Malappuram, authorities are already mobilizing rapid response teams to trace contacts, disinfect the patient’s surroundings, and educate the public about symptoms and preventive measures.

Although most outbreaks have been localized to South and Southeast Asia, Nipah virus is considered a global threat. The World Health Organization (WHO) includes it on the list of priority diseases for research and development, due to its potential to cause widespread epidemics and the lack of available countermeasures.

The U.S. Centers for Disease Control and Prevention (CDC) also closely monitors Nipah virus, emphasizing the importance of global health surveillance systems. As climate change, deforestation, and wildlife trade continue to increase human-animal interactions, the risk of zoonotic spillovers like Nipah is on the rise.

The emergence of a new Nipah case in Kerala is a critical reminder of the interconnectedness of human and animal health. While the virus is not currently spreading globally, the high fatality rate, airborne nature, and lack of treatment options make it essential to remain vigilant.

For residents in affected areas and globally the best approach is a combination of early reporting, awareness about transmission, and adherence to public health guidelines.

End of Article

Not Just COVID-19, Or Hepatitis B, Kennedy's New Vaccine Committee Plans To Change Chickenpox, Measles, Mumps And Rubella Shots

Updated Sep 18, 2025 | 10:28 AM IST

SummaryA U.S. vaccine advisory panel is reconsidering recommendations for chickenpox, measles, mumps, rubella, COVID-19, and hepatitis B shots. Experts warn reopening long-settled debates could confuse parents, weaken trust, and limit access, especially for low-income families relying on federal programs. Critics say the review risks undoing decades of protection against preventable childhood diseases.
Not Just COVID-19, Or Hepatitis B, Kennedy's New Vaccine Committee Plans To Change Chickenpox, Measles, Mumps And Rubella Shots

RF Kennedy Jr, Health Secretary, Source: AP

The future of childhood vaccinations in the U.S. is suddenly in question. Health Secretary Robert F. Kennedy Jr.’s newly restructured vaccine advisory committee is set to vote this week in Atlanta on whether to alter long-standing recommendations for several critical vaccines, including shots against chickenpox, measles, mumps, rubella, hepatitis B, and COVID-19.

The committee, known as the Advisory Committee on Immunization Practices (ACIP), plays a powerful role: its recommendations guide pediatricians nationwide and determine which shots are covered by the government-funded Vaccines for Children (VFC) program, a safety net for low-income families.

While some experts say the agenda looks like a routine review, others worry it could open the door to unnecessary confusion, weaken trust, and reduce access to vaccines that have long protected children from serious disease.

Also Read: Unique Symptoms Of Covid In 2025 And How Long Infection Now Last

Chickenpox and the MMRV Vaccine Debate

Before the chickenpox vaccine was licensed in 1995, nearly every American child contracted the disease. While often dismissed as a rite of passage with itchy rashes and mild fevers, chickenpox could also lead to severe complications like pneumonia, skin infections, brain swelling, and in rare cases, death. The virus, varicella, also lingers in the body and can resurface decades later as shingles, a painful nerve condition.

The introduction of the vaccine dramatically reduced cases and hospitalizations. In 2005, regulators approved a combination shot called MMRV, which bundled measles, mumps, rubella, and varicella vaccines into a single injection. Initially, health officials recommended the combo as the preferred option for the first dose in toddlers.

However, studies soon revealed a catch: children who received the MMRV shot were more likely to develop fevers, rashes, and in rare instances, febrile seizures compared with those who got separate MMR and varicella injections.

In response, the ACIP in 2009 updated its guidance, recommending separate shots for the first dose (typically given between ages 12–15 months) but allowing the combo shot for the second dose in preschool years.

Today, most pediatricians follow that approach. Still, the evidence hasn’t changed in over a decade. That raises eyebrows about why the Kennedy-led committee is reopening the debate now.

Public health experts caution that limiting the combined shot could make vaccination less convenient for families and potentially reduce uptake. Pediatric advisors warn that even small barriers, like two shots instead of one, can mean some kids fall behind.

Why Measles, Mumps, and Rubella Still Matter

While much of the attention is on chickenpox, the measles, mumps, and rubella (MMR) vaccine remains equally critical. Each of these viruses was once a common threat in childhood:

  • Measles can lead to pneumonia, brain swelling, and death.
  • Mumps can cause meningitis and, in boys, permanent infertility.
  • Rubella is especially dangerous for pregnant women, sometimes causing miscarriage or severe birth defects.

Before widespread vaccination began in the 1970s, hundreds of thousands of children in the U.S. contracted these diseases every year. Outbreaks have returned in recent years when vaccination rates dip, underscoring the importance of reliable and consistent recommendations.

Revisiting guidance without new evidence, experts say, risks fueling skepticism among parents already facing a flood of misinformation online.

The COVID-19 Vaccine Question

The COVID-19 shots are also on the table. Typically, ACIP renews recommendations annually for vaccines against respiratory viruses such as flu. But this June, Kennedy’s panel endorsed flu vaccines while staying silent on COVID-19.

Also Read: US Health Officials To Examine Covid Vaccine Effects In Pregnant Women And Kids

That silence matters. Earlier, Kennedy had already removed COVID-19 shots from CDC recommendations for healthy children and pregnant women, sparking lawsuits from pediatric groups who said the move endangered kids’ health.

The FDA recently narrowed the authorization of updated COVID-19 vaccines, limiting use for certain younger groups. If ACIP mirrors that without clarification, millions of children could lose federally funded access through the Vaccines for Children program. Experts warn this could leave families confused, especially since COVID-19 formulations update yearly, much like flu shots.

Revisiting Hepatitis B Vaccinations

Hepatitis B presents a different set of challenges. The virus can cause chronic liver infection, cirrhosis, and cancer. While adults often acquire it through sexual contact or sharing needles, newborns face the highest lifelong risk if exposed at birth.

Read More: Hepatitis B Vaccination Timeline For Children Under Review Without Scientific Data, Says Former CDC Director Susan Monarez

Since 2005, U.S. guidance has recommended that infants receive their first hepatitis B shot within 24 hours of birth. This approach significantly reduced cases of mother-to-child transmission, which often slipped through maternal screening programs. Studies show the newborn shot is safe and highly effective, preventing 85–95% of chronic infections.

Yet Kennedy’s committee has floated the idea of revisiting this recommendation, though experts note there is no new evidence suggesting safety concerns. Critics argue that questioning the birth dose now could reverse decades of progress.

Why the Stakes Are So High

Beyond the science, the politics surrounding these deliberations are unusual. Kennedy, once one of the nation’s most vocal vaccine skeptics, dismissed the 17-member ACIP earlier this year and replaced it with a panel that includes several anti-vaccine voices.

Historically, ACIP’s recommendations are based on careful review by subcommittees made up of pediatricians, infectious disease experts, pharmacists, and public health officials. Those subgroups sift through peer-reviewed studies, track outbreaks, and balance risks against benefits. But this time, critics say the process appears less about science and more about ideology.

Even if the committee doesn’t overturn long-standing guidance, simply reopening settled debates may erode confidence. Parents who hear that vaccines are “under review” might delay or decline shots, leaving children vulnerable.

Perhaps most worrisome: a restrictive vote could block coverage of these vaccines under the Vaccines for Children program, which supplies nearly half of all childhood shots in the U.S. Without it, low-income families could lose access, widening gaps in protection.

What Lies Ahead?

The stakes of this week’s ACIP votes go far beyond the meeting room in Atlanta. At issue is not just whether a child gets one shot or two, but whether the nation maintains decades of progress against diseases once considered inevitable.

Chickenpox, measles, mumps, rubella, hepatitis B, and COVID-19 vaccines have all proven their worth in protecting children from dangerous, sometimes deadly illnesses. Experts say undermining trust or restricting access now could reopen the door to outbreaks that public health worked so hard to shut.

End of Article

Hepatitis B Vaccination Timeline For Children Under Review Without Scientific Data, Says Former CDC Director Susan Monarez

Updated Sep 18, 2025 | 07:03 AM IST

SummaryVaccines have long been one of the greatest tools for protecting children’s health. As debates unfold, and the revelation by the former CDC Director Susan Monarez at the Senate hearing points that the stakes are not just about timing, they’re about whether preventable diseases stay in the past, or whether they return to threaten a new generation. Read on to know what the debate is all about.
Hepatitis B Vaccination Timeline For Children Under Review Without Scientific Data, Says Former CDC Director Susan Monarez

Credits: Canva and Reuters

The US childhood vaccination schedule has become the center of a heated debate and much attention is being drawn towards it after a Senate hearing revealed the possible changes to when critical shots like the hepatitis B vaccine are given. Susan Monarez, former director of Centers for Disease Control and Prevention (CDC) at the Senate Committee on Health, Education, Labor and Pensions hearing said that she was fired in August for refusing two demands by Health Secretary Robert F Kennedy Jr, which were: fire career agency officials and sign off vaccine recommendations without seeing any data.

“He said if I was unwilling to do both, I should resign,” she said. “I responded that I could not pre-approve recommendations without reviewing the evidence, and I had no basis to fire scientific experts.”

At stake is not just the timeline of immunization, but also health and safety of millions of children who rely on vaccines to protect them from life-threatening diseases.

“The concern is Robert F Kennedy [Jr.] is going to make America sicker again,” said Sen. Ed Markey, D-Mass. “They’re going to send us towards more disease, more death and more despair in our nation.”

Why Does Vaccine Schedule Matter?

The CDC, through its Advisory Committee on Immunization Practices (ACIP), sets the recommended vaccine schedule for children. While not mandatory, these guidelines strongly influence what health insurers cover and how doctors across the country advise parents.

For decades, the schedule has ensured that children are vaccinated against highly contagious diseases at the ages when they are most vulnerable. Changes to this timeline are not simply administrative, they have direct consequences on whether children remain protected against illnesses that once caused widespread suffering and death.

Debate Around The Hepatitis B Vaccine

One of the most debated issues that has risen is the hepatitis vaccine. It is from 1991 that the CDC recommended that babies must receive the first dose within 24 hours of birth, followed by additional doses at one month and between six to eighteen months.

This timing is not arbitrary. Hepatitis B is a viral infection that attacks the liver and can lead to cirrhosis, cancer, and lifelong health complications. Critically, the risk of developing chronic hepatitis B depends on the age at which a person is infected. Babies infected at birth have up to a 90% chance of developing chronic infection. Adults, by comparison, have only about a 5% chance.

Because many mothers are unaware they carry the virus, the birth dose serves as a crucial safeguard. It blocks transmission at the earliest stage, preventing lifelong illness and premature deaths.

So, What Could Change?

Sen. Bill Cassidy, R-La., the committee’s chair, asked Monarez if Kennedy had told her he was going to change the childhood vaccination schedule. “He said that the childhood vaccine schedule would be changing starting in September, and I needed to be on board with it,” Monarez said.

What is being proposed contradicts the CDC recommendation of hepatitis shot being the first one for a child to receive within 24 hours of being born. Testimony at the Senate hearing suggested that the vaccine schedule could be revised to delay the first dose of the hepatitis B shot until age 4. Former CDC officials raised alarms that this proposal was not based on scientific data but rather political direction.

If implemented, such a shift would mean babies could go unprotected during the period when they are most at risk of contracting hepatitis B from their mothers or close contacts. Experts warned this would undo decades of progress in reducing infant infections, from 20,000 cases annually before 1991 to fewer than 20 per year today.

Risks of Delaying Vaccination

Delaying hepatitis B vaccination could open the door to a resurgence of preventable infections. Even if mothers are screened during pregnancy, screening isn’t perfect, and some may acquire the infection late in pregnancy or go undiagnosed. Without the immediate protection of the birth dose, babies would be vulnerable.

Moreover, shifting vaccines later in childhood carries another risk: missed doses. Studies show that adherence to vaccines is highest in infancy, when routine well-baby visits are frequent. Delaying could mean some children never get fully vaccinated at all.

The consequences are not minor. Untreated hepatitis B leads to chronic infection in most infants, setting them on a path toward liver damage, cirrhosis, and cancer later in life.

Concerns for Childhood Immunization

The hepatitis B vaccine isn’t the only one under review. The same advisory panel is expected to revisit recommendations for measles, chickenpox, and the updated COVID-19 shot.

Also Read: US Health Officials To Examine Covid Vaccine Effects In Pregnant Women And Kids

Critics worry that altering the established childhood schedule without thorough scientific review could destabilize public trust and increase preventable outbreaks.

The controversy comes at a time when confidence in public health agencies is already slipping. According to a recent KFF poll, trust in the CDC dropped from 63% in 2023 to 57% in 2025. Changes seen as politically motivated, rather than evidence-driven, could erode that trust even further.

Why Science-Based Decisions Are Essential

Experts stress that vaccination decisions should be grounded in data, not politics. The success of public health in the U.S., from reducing measles deaths to nearly eliminating mother-to-child hepatitis B transmission—has hinged on science-led policymaking.

Sen. Bill Cassidy, a gastroenterologist, reminded lawmakers that the hepatitis B vaccine transformed infant health in America: “Before 1991, as many as 20,000 babies were infected with hepatitis B each year. Now, fewer than 20 babies annually get the virus from their mother.”

Such achievements highlight the life-saving role of evidence-based vaccination. Undoing or weakening these protections without compelling scientific justification risks reversing decades of progress.

What Comes Next?

The ACIP meeting will be pivotal in determining the future of the childhood vaccine schedule. If changes are recommended, they could reshape how millions of American children are immunized. However, for many experts, the principle remains clear: any adjustments must be backed by rigorous data and public health expertise.

End of Article

US Health Officials To Examine Covid Vaccine Effects In Pregnant Women And Kids

Health and Me

Updated Sep 18, 2025 | 12:00 AM IST

SummaryFederal health officials are reviewing safety data on COVID-19 vaccines in pregnant women and children and may also re-evaluate guidance for older adults. Here’s what you need to know.
US Health Officials To Examine Covid Vaccine Effects In Pregnant Women And Kids

Credits: Canva

Federal health officials are taking a closer look at the safety of COVID-19 vaccines in pregnant women and children, while also weighing updates to recommendations for older adults.

According to U.S. News, the Food and Drug Administration (FDA) is reviewing reports of possible birth defects following vaccination during pregnancy and is preparing data on deaths in children after receiving COVID shots.

The review will be presented during a September 18-19, 2025, meeting with the Centers for Disease Control and Prevention’s (CDC) vaccine advisory committee, CNN reported. Experts emphasise that the Vaccine Adverse Event Reporting System (VAERS), one of the primary tools being used in the review, is a monitoring system meant to detect potential safety signals. It does not establish that vaccines directly caused the reported health problems.

What Is VAERS?

The Vaccine Adverse Event Reporting System (VAERS) is designed to act as an early-warning tool, flagging potential safety signals that may warrant further study. “VAERS is a system that generates hypotheses,” explained Dr Demetre Daskalakis, who recently stepped down as director of the CDC’s National Center for Immunization and Respiratory Diseases, in an interview with CNN.

So far, large-scale studies have continued to show that COVID-19 vaccines are safe in pregnancy. The CDC has tracked outcomes in more than 23,000 pregnant women through one registry and more than 45,000 in another database, finding no increased risk of miscarriage, major birth defects, or other complications. Similarly, Pfizer reported that rates of birth defects in vaccinated participants during a clinical trial were comparable to those in the general population.

The CDC advisory committee is also expected to discuss whether vaccine guidance for older adults should be revised. While COVID vaccines are currently approved for adults 65 and older, as well as younger adults at high risk of severe illness, the panel may consider recommending them mainly for those 75 and older, or for younger individuals with underlying conditions.

ALSO READ: Is 'Stratus' COVID Variant The Pandemic’s Next Chapter In 2025 With New Symptoms?

New COVID Variant ‘Stratus’ Dominates U.S. Cases

COVID-19 activity remained high across the United States during the first week of September, according to fresh data from the Centers for Disease Control and Prevention (CDC). Despite the confusion around emerging strains, shifting vaccine guidelines, and cuts to vaccine development funding, the agency continues to track cases, hospitalisations, and deaths on a weekly basis.

For the four weeks ending August 30, projections show that a new variant called XFG. nicknamed “Stratus” accounted for 78 percent of infections nationwide. The next most common strains were NB.1.8.1 at 14 percent and LP.8.1 at 3 percent.

ALSO READ: Ozempic Users Found To Age Back By More Than 3 Years, Finds New Trial; Peer Review Pending

What Is the ‘Stratus’ Variant?

XFG is a late-summer Omicron offshoot and a recombinant strain, formed by blending two earlier lineages: F.7 and LP.8.1.2. Scientists say the variant may carry mutations that help it slip past parts of the immune system more effectively, though there is no evidence yet that it spreads faster than previous strains.

The CDC advises people to watch for familiar COVID-19 symptoms, which continue to include:

  1. Fever or chills
  2. Cough
  3. Fatigue
  4. Sore throat
  5. Loss of taste or smell
  6. Congestion
  7. Muscle aches
  8. Shortness of breath
  9. Headache
  10. Nausea or vomiting

End of Article